Comparison of Gadobutrol and Gadobenate Dimeglumin for Delayed Enhancement Cardiac MRI

Single Dose Gadobutrol in Comparison to Single Dose Gadobenate Dimeglumine for Magnetic Resonance Imaging of Chronic Myocardial Infarction at 3 Tesla

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01655290

Acronym

Gadovit

Enrollment

Registered

2012-08-01

Start date

2012-08-31

Completion date

2014-06-30

Last updated

2020-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subacute/Chronic Myocardial Infarction

Brief summary

This study aims at evaluating the diagnostic efficacy of Gadobutrol versus Gadobenate dimeglumine at similar dose of 0.1mmol/kg for assessment of myocardial infarction by delayed enhancement cardiac Magnetic Resonance Imaging

Interventions

OTHERGadovist® (Gadobutrol), Multihance® (Gadobenate dimeglumin)

Other (Diagnostic)

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

DIAGNOSTIC

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of myocardial infarction * Age ≥ 18 years and ≤ 80 years * Informed consent * Male patients as well as female patients using contraceptives

Exclusion criteria

* Patients with a heart pacemaker, with magnetic material or other magnetic implants. * Renal failure (GFR \<30ml/min) * Patients with known allergy to a Gadolinium-containing contrast agent * Drugs or alcohol addiction, dementia

Design outcomes

Primary

Measure	Time frame
Efficacy (contrast-to-noise ratio)	—

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026